Female Trichomoniasis Vaginalis - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: FD67D0E64B55EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Female Trichomoniasis Vaginalis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Female Trichomoniasis Vaginalis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Female Trichomoniasis Vaginalis Understanding

The DelveInsight Female Trichomoniasis Vaginalis epidemiology report gives a thorough understanding of the Female Trichomoniasis Vaginalis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Female Trichomoniasis Vaginalis in the US, Europe, and Japan. The report covers the detailed information of the Female Trichomoniasis Vaginalis epidemiology scenario in seven major countries (US, EU5, and Japan).

Female Trichomoniasis Vaginalis Epidemiology Perspective by DelveInsight

The Female Trichomoniasis Vaginalis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Female Trichomoniasis Vaginalis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Female Trichomoniasis Vaginalis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Female Trichomoniasis Vaginalis Detailed Epidemiology Segmentation

The Female Trichomoniasis Vaginalis epidemiology covered in the report provides historical as well as forecasted Female Trichomoniasis Vaginalis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Female Trichomoniasis Vaginalis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Female Trichomoniasis Vaginalis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Female Trichomoniasis Vaginalis Epidemiology Report and Model provide an overview of the global trends of Female Trichomoniasis Vaginalis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Female Trichomoniasis Vaginalis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Female Trichomoniasis Vaginalis
• The report provides the segmentation of the Female Trichomoniasis Vaginalis epidemiology

Report Highlights

• 11-year Forecast of Female Trichomoniasis Vaginalis epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Female Trichomoniasis Vaginalis
• Cases of Female Trichomoniasis Vaginalis by Mutation Types
• Female Trichomoniasis Vaginalis Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Female Trichomoniasis Vaginalis?
• What are the key findings pertaining to the Female Trichomoniasis Vaginalis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Female Trichomoniasis Vaginalis across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Female Trichomoniasis Vaginalis?
• What are the currently available treatments of Female Trichomoniasis Vaginalis?

Reasons to buy

The Female Trichomoniasis Vaginalis Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Female Trichomoniasis Vaginalis market
• Quantify patient populations in the global Female Trichomoniasis Vaginalis market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Female Trichomoniasis Vaginalis therapeutics in each of the markets covered
• Understand the magnitude of Female Trichomoniasis Vaginalis population by its epidemiology
• The Female Trichomoniasis Vaginalis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF FEMALE TRICHOMONIASIS VAGINALIS

3. FEMALE TRICHOMONIASIS VAGINALIS: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Female Trichomoniasis Vaginalis Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Female Trichomoniasis Vaginalis Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Female Trichomoniasis Vaginalis Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Female Trichomoniasis Vaginalis Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Female Trichomoniasis Vaginalis Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Female Trichomoniasis Vaginalis Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Female Trichomoniasis Vaginalis Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Female Trichomoniasis Vaginalis Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Female Trichomoniasis Vaginalis Treatment and Management
6.2. Female Trichomoniasis Vaginalis Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Female Trichomoniasis Vaginalis Epidemiology in 7MM (2019-2032)
Table 2: Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Female Trichomoniasis Vaginalis Epidemiology in the United States (2019-2032)
Table 4: Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Female Trichomoniasis Vaginalis Epidemiology in Germany (2019-2032)
Table 6: Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Female Trichomoniasis Vaginalis Epidemiology in France (2019-2032)
Table 8: Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Female Trichomoniasis Vaginalis Epidemiology in Italy (2019-2032)
Table 10: Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Female Trichomoniasis Vaginalis Epidemiology in Spain (2019-2032)
Table 12: Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Female Trichomoniasis Vaginalis Epidemiology in the United Kingdom (2019-2032)
Table 14: Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Female Trichomoniasis Vaginalis Epidemiology in Japan (2019-2032)
Table 16: Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Female Trichomoniasis Vaginalis Epidemiology in 7MM (2019-2032)
Figure 2 Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Female Trichomoniasis Vaginalis Epidemiology in the United States (2019-2032)
Figure 4 Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Female Trichomoniasis Vaginalis Epidemiology in Germany (2019-2032)
Figure 6 Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Female Trichomoniasis Vaginalis Epidemiology in France (2019-2032)
Figure 8 Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Female Trichomoniasis Vaginalis Epidemiology in Italy (2019-2032)
Figure 10 Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Female Trichomoniasis Vaginalis Epidemiology in Spain (2019-2032)
Figure 12 Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Female Trichomoniasis Vaginalis Epidemiology in the United Kingdom (2019-2032)
Figure 14 Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Female Trichomoniasis Vaginalis Epidemiology in Japan (2019-2032)
Figure 16 Female Trichomoniasis Vaginalis Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report